Tagged with M

R&D With the USD 62 billion deal from Japan’s Takeda Pharmaceutical to buy Irish firm Shire finally agreed after months of wrangling, we asked PharmaBoardroom’s readers whether this deal would herald a flurry of mergers and acquisitions (M&As) within the pharma world. “Biotech and pharma M&A activity dropped to its lowest…

Canada Bob McLay, vice president and general manager of Sobi in Canada, discusses how innovation and collaboration with regulators and payers are helping Sobi to bring its medicines to Canadians suffering from rare diseases, while emphasizing the importance of an adequate rare disease framework to streamline this process in the future.…

Portugal Filipa Costa returned to Portugal in September 2016 to take on the leadership of the fastest growing multinational affiliate in the country – Janssen. In this interview, she reveals her intention to change the perception of clinical trials in Portugal, current strategies to promote government-industry collaboration and the keys to…

Portugal Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on the strengths of OTC medicines. While touching on pertinent topics that affect the entire pharmaceutical production value chain, Costa highlights…

Poland The value of Poland’s pharmaceutical exports shot from USD 501 million in 2005 to USD 3.475 billion in 2015, a total growth of an astounding 590% and a compound annual growth rate of 21%. Most exports go to Europe (80%) but Asian markets are becoming increasingly important to Poland and…

Poland The Top 20 pharma companies in the Polish retail market for 2017 ranked by sales in USD millions. Domestic champion Polpharma leads the way, followed by international players Teva and Bayer.

India Swati Jajodia, managing director of Swati Spentose discusses her commitment to tackling underserved diseases and the company’s approach to bringing pentosan polysulfate to global markets while working with Key Opinion Leaders and CMEs in raising awareness about interstitial cystitis (IC).    Could you please introduce Swati Spentose to our international…

UK Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls for more creativity in HTA processses in a collaborative effort to bring innovation to patients faster. What is the scope…

Spain Ángel Luis Rodríguez de la Cuerda, secretary general of AESEG, the trade association of generic producers in Spain, discusses the initiatives that the organization is undertaking to develop a true generic culture in the country and a new proposal changing the requirement for originator drugs to remain at the same…

China Tian Yaolin, CEO of Shenzhen Govita Medical Laboratory, shares the exciting story of Govita’s start-up in the past two years; their robust and innovative business model centered on healthcare management and preventive medicine; and the synergies they are leveraging between their Hong Kong and Shenzhen affiliates. Yaolin, as the CEO…

India Jai and Sameer Hiremath of Hikal provide insights into the main trends shaping the Indian and global CDMO industry. They articulate how Hikal’s long-standing focus on quality standards, regulatory compliance, and good governance has enabled the company to avoid regulatory issues and gain the trust of the world’s most respected…

Portugal A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017. The situation is further enhanced by increasing inter-stakeholder communication and transparency, and a targeted focus on removing bureaucracy barriers, from…